-Anders Bylock Researcher Activity Profile

Research Author Detailed Information 

Anders Bylock Publication Rate By Year

Anders Bylock has published 5 paper(s) in 2007, 3 paper(s) in 2008, for a total of 8 research publications in total.

Anders A Bylock Author Information

LAST NAME: bylock

FIRST NAME: anders

INITIALS: A

AFFILIATION:

Papers

Anders Bylock's Publication Record

1. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Year Published: 2007
Department of Cardiology and Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. christina.christersson@akademiska.se
2. Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety. Year Published: 2007
Thrombosis Research Institute, London, UK.
3. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Year Published: 2007
International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK. oladahl@start.no
4. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Year Published: 2008
5. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Year Published: 2008
6. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Year Published: 2007
International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK. oladahl@start.no
7. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Year Published: 2007
Department of Cardiology and Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. christina.christersson@akademiska.se
8. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri? Year Published: 2008
AstraZeneca R&D, Medical Science, Mölndal, Sweden. marco.tangelder@astrazeneca.com